Xcell Therapeutics Inc. (KOSDAQ:373110)
South Korea flag South Korea · Delayed Price · Currency is KRW
1,965.00
+72.00 (3.80%)
Nov 20, 2025, 3:30 PM KST

Xcell Therapeutics Ratios and Metrics

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202019
Period Ending
Nov '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
20,70744,384----
Upgrade
Enterprise Value
22,70738,298----
Upgrade
Last Close Price
1893.003373.54----
Upgrade
PS Ratio
13.9422.95----
Upgrade
PB Ratio
5.114.87----
Upgrade
P/TBV Ratio
6.115.17----
Upgrade
EV/Sales Ratio
15.2919.80----
Upgrade
Debt / Equity Ratio
1.400.632.730.690.383.54
Upgrade
Asset Turnover
0.150.140.090.050.100.05
Upgrade
Inventory Turnover
3.024.444.014.673.872.48
Upgrade
Quick Ratio
0.731.900.361.192.831.18
Upgrade
Current Ratio
1.042.140.521.392.931.29
Upgrade
Return on Equity (ROE)
-981.05%-165.90%-170.80%-67.53%-102.65%-
Upgrade
Return on Assets (ROA)
-66.83%-42.63%-43.01%-26.46%-18.88%-26.46%
Upgrade
Return on Capital (ROIC)
-88.50%-49.18%-48.12%-28.23%-24.84%-108.77%
Upgrade
Return on Capital Employed (ROCE)
-149.90%-77.90%-177.90%-80.40%-30.90%-55.60%
Upgrade
Earnings Yield
-50.16%-21.50%----
Upgrade
FCF Yield
-43.97%-16.63%----
Upgrade
Buyback Yield / Dilution
-20.42%-13.14%-1.02%-5.71%-131.08%-107.45%
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.